We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Romatoid artrit ve spondiloartritte biyolojik DMARD'lar arasında geçiş ve nedenleri: TReasure gerçek yaşam verileri.
- Authors
Kalyoncu, Umut; Ertenli, Ali İhsan; Kücükşahin, Orhan; Dalkılıç, Hüseyin Ediz; Erden, Abdulsamet; Bes, Cemal; Kanıtez, Nilüfer Alpay; Kaşifoğlu, Timuçin; Kızılırmak, Pınar; Emmungil, Hakan; Coşkun, Belkis Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Aşkın; Akar, Servet; Ersözlü, Duygu; Yazısız, Veli; Bilge, Nazife Şule Yaşar; Kimyon, Gezmiş
- Abstract
Objective: To determine features of patients switching between biological (b) DMARDs in rheumatoid arthritis (RA) and spondyloarthritis (SpA) treatments and to investigate associated reasons. Methods: This multicenter, prospective, observational cohort study used the TReasure database in which web-based registration of RA and SpA patients are being performed in 15 centers across Turkey. In this study, switching rates between bDMARDs, associated reasons, and features were analyzed in patients continuing bDMARD treatments during their follow-up periods. Results: Analysis included 2115 RA patients and 3138 SpA patients, of whom 829 (39.2%) RA and 1165 (37.1%) SpA patients switched to another bDMARD and 1286 (60.8%) RA and 1973 (62.9%) SpA patients continued to receive their current therapies (continued group). Median follow-up duration was 3.7 (range: 0-58.4) years in RA patients and 3.8 (range: 0-45.1) years in SpA patients. Female proportion was higher in both RA and SpA patients in the switched group. The first bDMARD used was an anti-TNF in 60.9% of RA patients and another bDMARD in 39.1%. According to switching patterns between bDMARDs, of RA patients, 41% switched from one anti-TNF to another and 38.4% switched from one anti-TNF to a bDMARD with other mechanism of action. The main reasons for switching in both RA and SpA patients were primary or secondary ineffectiveness and side effects. Conclusion: Further data on compliance to bDMARD treatment and treatment discontinuation or switching from one bDMARD to another in rheumatologic patients are needed to improve outcomes of patients and to ensure rational use of health expenditures.
- Subjects
TURKEY; DRUG side effects; PATIENT compliance; RHEUMATOID arthritis; BIOCHEMICAL mechanism of action; FOLLOW-up studies (Medicine)
- Publication
Journal of Turkish Society for Rheumatology, 2019, Vol 11, Issue 1, p1
- ISSN
2651-2653
- Publication type
Article
- DOI
10.2399/raed.19.99608